319 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Conditions: Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
2 Recruiting Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Condition: Newly Diagnosed Ewing Sarcoma
Interventions: Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*
3 Active, not recruiting Efficacy and Safety Study of Idelalisib in Patients With Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytoid Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
4 Recruiting Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Conditions: Hematopoietic Stem Cell Transplantation;   Solid Tumor;   Transplantation, Autologous
Interventions: Drug: Ifosfamide;   Drug: Etoposide phosphate;   Drug: Mesna;   Biological: Granulocyte colony-stimulating factor;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Caboplatin
5 Recruiting ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: ERC1671;   Drug: GM-CSF;   Drug: Cyclophosphamide;   Drug: Oral Control (Sucrose pill);   Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%));   Drug: Bevacizumab
6 Recruiting Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Condition: Multiple Myeloma
Intervention:
7 Terminated A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
Condition: Cancer, Metastatic
Interventions: Drug: Carboplatin;   Drug: Pazopanib
8 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
9 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous Administration of Herceptin (Trastuzumab) in Women With HER2-Positive Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin];   Drug: docetaxel;   Drug: 5-fluorouracil;   Drug: epirubicin;   Drug: cyclophosphamide
10 Recruiting Stem Cell Collection With Ofatumumab
Condition: Lymphoma
Interventions: Drug: Ofatumumab;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Mesna;   Drug: G-CSF;   Procedure: Stem Cell Collection
11 Active, not recruiting High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET);   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Primary Systemic Amyloidosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Neuroblastoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Regional Neuroblastoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: etoposide;   Drug: cyclophosphamide;   Drug: carmustine;   Drug: melphalan;   Drug: busulfan;   Drug: carboplatin;   Drug: thiotepa;   Radiation: total-body irradiation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
12 Recruiting Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
Condition: Myeloid Hematological Malignancies
Interventions: Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Cord Blood Stem Cell Infusion
13 Recruiting Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Conditions: Childhood Mixed Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliosarcoma
Interventions: Drug: veliparib;   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
14 Recruiting Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
15 Recruiting A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Childhood Cerebral Adrenoleukodystrophy (CCALD)
Conditions: Childhood Cerebral Adrenoleukodystrophy;   (X-linked Adrenoleukodystrophy Cerebral Childhood)
Interventions: Genetic: Lenti-D Drug Product;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Filgrastim
16 Not yet recruiting Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: SAHA;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplant (SCT);   Drug: Palifermin;   Drug: Dexamethasone;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine
17 Active, not recruiting A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera];   Drug: Fludarabine;   Drug: Cyclophosphamide
18 Completed Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
19 Active, not recruiting A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: rituximab [MabThera/Rituxan];   Drug: fludarabine;   Drug: cyclophosphamide
20 Completed 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Condition: Breast Cancer
Interventions: Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Methotrexate;   Drug: 5-fluorouracil

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years